SCHEMBL17181753

SCHEMBL17181753

COc1c[c]ccc1OCCN1CCNCC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
LTA4H P09960 2/20 0.42
CYP1A2 P05177 1/20 0.41
CHRM2 P08172 1/20 0.41
SLC6A4 P31645 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
APOBEC3A P31941 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
QPCT Q16769 2/20 0.39
SIGMAR1 Q99720 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3512153 0.92 POLB (0.38) POLBLTA4HCYP1A2CHRM2SLC6A4
SCHEMBL2976035 0.87 POLB (0.56) POLBLTA4HCYP1A2KDM4EALDH1A1
SCHEMBL3514397 0.86 POLB (0.44) POLBLTA4HTDP1
SCHEMBL2976094 0.86 POLB (0.55) POLBLTA4HCYP1A2KDM4EGAA
SCHEMBL3513581 0.86 HRH2 (0.39) CYP1A2CHRM2SLC6A4OPRD1OPRK1
SCHEMBL3513735 0.84 POLB (0.43) POLBLTA4HKDM4EALDH1A1TDP1
SCHEMBL3514630 0.84 SYK (0.54) POLBKDM4EALDH1A1TDP1
SCHEMBL7451023 0.82 POLB (0.56) POLBLTA4HCYP1A2KDM4EALDH1A1
SCHEMBL3436048 0.81 POLB (0.55) POLBLTA4HKDM4EALDH1A1TDP1
SCHEMBL4576591 0.81 POLB (0.55) POLBLTA4HCYP1A2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2925319-B1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES UNIV ROCHESTER (US) 2019-01-09 EP disclosed
EP-3037421-A1 MLK INHIBITORS AND METHODS OF USE University Of Rochester (US) 2016-06-29 EP disclosed
EP-2379561-B1 MLK INHIBITORS AND METHODS OF USE UNIV ROCHESTER (US) 2015-11-04 EP disclosed
US-20150297587-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297587-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES MLKL, MARCKS, MAP3K4 POLB 664/4885LTA4H 2386/4885CYP1A2 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.